MKSI

MKS is executing a genuine operational recovery. FY2025 revenue grew 9.6% to $3.93B, net income jumped 55.3% to $295M and diluted EPS rose 55.5% to $4.37, with operating cash flow up 22.2% to $645M and a clean PCAOB audit opinion (including effective internal controls). After the FY2023 net loss of $1.84B, the trajectory is clearly improving and the balance sheet is healing — stockholders' equity grew 17.1% to $2.72B and long-term debt fell 7.5% to $4.15B. So the quality concern is not solvency; it is valuation versus the kind of business this is.

This is a cyclical supplier to semiconductor, electronics-manufacturing and automotive capex — markets the 10-K itself flags as subject to 'fluctuations in capital spending' and 'intense competition, rapid technological and market changes.' The through-cycle margins prove it: net margin is only 7.5%, operating margin 13.4% and ROE just 10.8%, and revenue has been roughly flat ($3.55B-$3.93B) since FY2022. At $406.37 the stock trades at 93x trailing diluted EPS and 7.0x sales. For a leveraged, single-digit-net-margin cyclical, that multiple discounts a sustained up-cycle that the data does not yet evidence; one soft quarter of semi capex and the earnings denominator compresses while the multiple has nowhere to hide.